Related Experiment Video
Updated: Jun 8, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2
Kosuke Matsuo1, Mirela Delibegovic, Izumi Matsuo
1Department of Nutrition, University of California, Davis, California 95616, USA.
Abstract:
The Src homology 2 domain-containing protein-tyrosine phosphatase Shp2 has been implicated in a variety of growth factor signaling pathways, but its role in insulin signaling has remained unresolved. In vitro studies suggest that Shp2 is both a negative and positive regulator of insulin signaling, although its physiological function in a number of peripheral insulin-responsive tissues remains unknown. To address the metabolic role of Shp2 in the liver, we generated mice with either chronic or acute hepatic Shp2 deletion using tissue-specific Cre-LoxP and adenoviral Cre approaches, respectively. We then analyzed insulin sensitivity, glucose tolerance, and insulin signaling in liver-specific Shp2-deficient and control mice. Mice with chronic Shp2 deletion exhibited improved insulin sensitivity and increased glucose tolerance compared with controls. Acute Shp2 deletion yielded comparable results, indicating that the observed metabolic effects are directly caused by the lack of Shp2 in the liver. These findings correlated with, and were most likely caused by, direct dephosphorylation of insulin receptor substrate (IRS)1/2 in the liver, accompanied by increased PI3K/Akt signaling. In contrast, insulin-induced ERK activation was dramatically attenuated, yet there was no effect on the putative ERK site on IRS1 (Ser(612)) or on S6 kinase 1 activity. These studies show that Shp2 is a negative regulator of hepatic insulin action, and its deletion enhances the activation of PI3K/Akt pathway downstream of the insulin receptor.
Insights
Shp2 protein negatively regulates insulin signaling in the liver. Deleting Shp2 in liver cells improves insulin sensitivity and glucose tolerance by enhancing PI3K/Akt pathway activation.
Area of Science:
- Metabolic signaling
- Protein tyrosine phosphatases
- Insulin action
Background:
- The role of Src homology 2 domain-containing protein-tyrosine phosphatase (Shp2) in insulin signaling is complex, with in vitro studies suggesting both positive and negative regulatory functions.
- Its physiological role in peripheral insulin-responsive tissues, particularly the liver, remains largely unknown.
Purpose of the Study:
- To investigate the metabolic role of Shp2 in the liver and its impact on insulin signaling and glucose homeostasis.
- To determine if Shp2 acts as a negative regulator of hepatic insulin action.
Main Methods:
- Generation of mice with chronic or acute liver-specific Shp2 deletion using Cre-LoxP and adenoviral Cre systems.
- Analysis of insulin sensitivity, glucose tolerance, and insulin signaling pathways (PI3K/Akt, ERK) in liver-specific Shp2-deficient mice and controls.
Main Results:
- Chronic and acute hepatic Shp2 deletion led to improved insulin sensitivity and glucose tolerance compared to control mice.
- Shp2 deletion resulted in direct dephosphorylation of insulin receptor substrate (IRS)1/2 in the liver.
- Enhanced PI3K/Akt signaling was observed downstream of the insulin receptor, while insulin-induced ERK activation was attenuated.
Conclusions:
- Shp2 is a negative regulator of hepatic insulin action.
- Deletion of Shp2 in the liver enhances insulin sensitivity and glucose tolerance by promoting PI3K/Akt pathway activation.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

